- Home
- KPTI vs ABLV Comparison
KPTI vs ABLV Comparison
Compare KPTI & ABLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ABLV
- Stock Information
- Founded
- KPTI 2008
- ABLV 2015
- Country
- KPTI United States
- ABLV China
- Employees
- KPTI N/A
- ABLV N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ABLV
- Sector
- KPTI Health Care
- ABLV
- Exchange
- KPTI Nasdaq
- ABLV Nasdaq
- Market Cap
- KPTI 33.6M
- ABLV 38.1M
- IPO Year
- KPTI 2013
- ABLV N/A
- Fundamental
- Price
- KPTI $4.21
- ABLV $0.96
- Analyst Decision
- KPTI Strong Buy
- ABLV
- Analyst Count
- KPTI 5
- ABLV 0
- Target Price
- KPTI $61.00
- ABLV N/A
- AVG Volume (30 Days)
- KPTI 172.5K
- ABLV 48.4K
- Earning Date
- KPTI 05-07-2025
- ABLV 01-01-0001
- Dividend Yield
- KPTI N/A
- ABLV N/A
- EPS Growth
- KPTI N/A
- ABLV N/A
- EPS
- KPTI N/A
- ABLV N/A
- Revenue
- KPTI $145,237,000.00
- ABLV $130,087,189.00
- Revenue This Year
- KPTI $4.87
- ABLV N/A
- Revenue Next Year
- KPTI $16.29
- ABLV N/A
- P/E Ratio
- KPTI N/A
- ABLV N/A
- Revenue Growth
- KPTI N/A
- ABLV N/A
- 52 Week Low
- KPTI $3.51
- ABLV $0.55
- 52 Week High
- KPTI $21.30
- ABLV $2.06
- Technical
- Relative Strength Index (RSI)
- KPTI 37.33
- ABLV 50.53
- Support Level
- KPTI $3.83
- ABLV $0.88
- Resistance Level
- KPTI $4.36
- ABLV $1.15
- Average True Range (ATR)
- KPTI 0.55
- ABLV 0.12
- MACD
- KPTI 0.13
- ABLV -0.00
- Stochastic Oscillator
- KPTI 25.64
- ABLV 50.13
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.